Analyst Price Target is $21.75
▲ +343.88% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocuphire Pharma in the last 3 months. The average price target is $21.75, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 343.88% upside from the last price of $4.90.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Ocuphire Pharma.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.